Mainstream

AstraZeneca beats Q4 top-line and bottom-line estimates; initiates FY25 outlook

AstraZeneca beats Q4 top-line and bottom-line estimates; initiates FY25 outlook

Post Contentazn, azncfRead More

You might also be interested in reading Rio Tinto bets Trump will approve giant U.S. copper project held up for 12 years – FT.

February 6, 2025
In Mainstream